TICKERNERD
Menu
PRQRPRQRHealthcare · Biotechnology

PRQR Stock Forecast: ProQR Therapeutics NV Price Predictions for 2026-2027

Last close, 8 Oct 2026
$1.57
−3.68% on the day

The 9 Wall Street analysts covering ProQR Therapeutics NV hold a median 12-month price target of $8 — +409.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 48 of 100 as at 8 Oct 2026 — in the lower half.

Market cap
$232.8M
Ticker Nerd rank
48 / 100
Median analyst target
$8.00
Analysts covering
9
Revenue$8.8M+129.5% y/y
Operating income−$8.8M
Net income−$8.7M
Free cash flow−$12.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.7%
1M
−23.4%
YTD
−22.3%
1Y
−33.5%
From 52W high
−48.5%
From 52W low
+14.6%
$1.37
$3.05
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PRQR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores ProQR Therapeutics NV on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
48 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
74
Growth
68
Size
66
Issuance
50
Value
47
Quality
40
Momentum
32
Accruals
32
Volatility
25

Revisions (74): Analysts have, on balance, been raising their forecasts.

Volatility (25): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

PRQR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PRQR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00Jan 26Apr 26Jul 26Oct 26PRQRHigh $10.00Median $8.00Low $3.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
9 Buy0 Hold0 Sell
Low $3.00Median $8.00High $10.00

The green dot is the last close — the median target sits +409.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 1 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
1 Oct 2026Chardan CapitalMaintainsBuy$3.00
1 Oct 2026HC Wainwright & Co.MaintainsBuy$12 → $8.00
20 Aug 2026B of A SecuritiesInitiatesBuy—
20 Aug 2026B of A SecuritiesInitiatesBuy$8.00
29 June 2026Evercore ISI GroupMaintainsOutperform$5.00 → $6.00
29 June 2026Evercore ISI GroupMaintainsOutperform—
26 June 2026Chardan CapitalMaintainsBuy—
26 June 2026Chardan CapitalMaintainsBuy$4.00 → $3.00
26 June 2026Jones TradingMaintainsBuy—
26 June 2026Jones TradingMaintainsBuy$11 → $10
9 Apr 2026Chardan CapitalMaintainsBuy—
4 Nov 2025Chardan CapitalMaintainsBuy—
8 Aug 2025Chardan CapitalMaintainsBuy—
27 June 2025Cantor FitzgeraldReiteratesOverweight—
27 June 2025JMP SecuritiesReiteratesMarket Outperform—
13 May 2025OppenheimerMaintainsOutperform—
29 Apr 2025Evercore ISI GroupInitiatesOutperform—
14 Mar 2025Chardan CapitalMaintainsBuy—
14 Mar 2025HC Wainwright & Co.MaintainsBuy—
12 Feb 2025Jones TradingInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PRQR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

PRQR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, ProQR Therapeutics NV returned −33.5% against +16.2% for the S&P 500, dividends included.

PRQR vs S&P 500, last 12 monthsTotal return, rebased to 100
60708090100110120Jan 26Apr 26Jul 26Oct 26PRQRS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PRQR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

ProQR Therapeutics NV (PRQR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−4.0×

Cheaper than 89% of US stocks

Price / sales
12.6×

Cheaper than 12% of US stocks

Price / book
2.6×

Cheaper than 35% of US stocks

EV / EBITDA
−3.1×

Cheaper than 76% of US stocks

Growth & margins
Revenue growth (YoY)
120.4%

Higher than 94% of US stocks

Earnings growth (YoY)
129.5%

Higher than 87% of US stocks

Gross margin
—
Operating margin
−100.7%

Higher than 14% of US stocks

Net margin
−228.2%

Higher than 2% of US stocks

Returns & dividend
Return on equity
−57.4%

Higher than 20% of US stocks

Return on assets
−19.8%

Higher than 19% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

ProQR Therapeutics NV (PRQR) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • ProQR Therapeutics NV has a market value of $232.8M and an enterprise value of $147.5M.

  • Revenue in the twelve months to 30 June 2026: $18.4M. The latest quarter grew 120.4% year on year.

  • Net income over the same four quarters: −$42.0M, a −228.9% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$50.2M.

  • Shares outstanding: 141.1M.

  • Trailing P/E: −4.0×; forward P/E: −3.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • ProQR Therapeutics NV employs 186 people — $99K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

PRQR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PRQRProQR Therapeutics NV$232.8M
48
PLXProtalix Biotherapeutics, Inc.$217.5M
92
LYELLyell Immunopharma, Inc.$215.4M
64
SIONSionna Therapeutics, Inc.$218.7M
30
TRDAEntrada Therapeutics, Inc.$214.7M
52
ALECAlector, Inc.$220.5M
50
GLSIGreenwich LifeSciences, Inc.$222.2M
42

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own ProQR Therapeutics NV — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PRQR news & analysis

ProQR Reports First Human Validation of RNA Editing Platform in Liver Disease

MarketBeat · 2 Oct 2026positive

ProQR Therapeutics announced first-in-human data for AX-0810, providing dose-dependent evidence that its RNA-editing approach can modulate NTCP, a liver transporter involved in bile acid uptake. The company is advancing NTCP programs for cholestatic liver diseases, initially focusing on pediatric biliary atresia.

Why it matters — This marks the first human validation of ProQR's RNA-editing platform, a key step for its liver disease pipeline that PRQR watchers would be following closely.

ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call Transcript

Seeking Alpha · 30 Sept 2026neutral

ProQR Therapeutics N.V. (PRQR) held a shareholder/analyst call, the transcript of which has been published on Seeking Alpha. The excerpt provided only indicates that the call transcript is available, without detailing the content of the discussion.

Why it matters — A PRQR watcher would care because the transcript provides insight into management commentary and company updates from the official call.

ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI Advisor

GlobeNewsWire · 23 Sept 2026positive

ProQR announced the appointment of Chris Hart as Chief Data and AI Officer and the addition of Thomas Wolf to its Board of Directors as Strategic AI Advisor. These appointments support ProQR's strategy to scale AI across drug discovery and development using its Axiomer RNA editing platform and pipeline program AX-0811.

Why it matters — The appointments signal ProQR's expanded focus on AI-enabled drug discovery, which directly supports its ongoing development programs and upcoming clinical data readouts across four development programs.

ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026

GlobeNewsWire · 9 Sept 2026positive

ProQR Therapeutics announced that the first participant has been dosed in the Phase 1 clinical trial of AX-0811 in healthy volunteers. The company also announced a virtual investor and analyst educational event scheduled for September 30, 2026.

Why it matters — This marks the initiation of clinical development for AX-0811, an RNA-editing candidate based on ProQR's Axiomer platform, giving PRQR watchers an early read on the program's progress.

ProQR to Participate in Upcoming Investor Conferences in September 2026

GlobeNewsWire · 2 Sept 2026neutral

ProQR Therapeutics announced it will participate in upcoming investor conferences scheduled for September 2026. The company, headquartered in Leiden, Netherlands and Cambridge, Massachusetts, made the announcement via press release on September 2, 2026.

Why it matters — This gives ProQR watchers an opportunity to hear management's latest updates on the company's pipeline and business at upcoming investor events.

FAQ

Frequently asked questions about PRQR stock

What is the PRQR stock price forecast for 2026-2027?

The 9 Wall Street analysts covering ProQR Therapeutics NV have a median 12-month price target of $8, with estimates ranging from $3 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PRQR stock a buy right now?

Of the 9 analysts covering ProQR Therapeutics NV, 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks ProQR Therapeutics NV 48 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PRQR?

As at 8 Oct 2026, ProQR Therapeutics NV ranks 48 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (74 of 100).

Will PRQR stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies +409.6% from the last close, and Ticker Nerd's factor model ranks ProQR Therapeutics NV 48 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PRQR stock forecast for 2030?

No analyst covering ProQR Therapeutics NV publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PRQR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $10 over the next 12 months.

How has PRQR stock performed over the past year?

ProQR Therapeutics NV returned -33.5% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does ProQR Therapeutics NV do?

ProQR Therapeutics N.V. Ordinary Shares represent ownership in ProQR Therapeutics N.V., a clinical-stage biotechnology company focused on RNA-based medicines.

What is the latest news on PRQR?

The most recent item we track (MarketBeat, 2 Oct 2026): "ProQR Reports First Human Validation of RNA Editing Platform in Liver Disease". ProQR Therapeutics announced first-in-human data for AX-0810, providing dose-dependent evidence that its RNA-editing approach can modulate NTCP, a liver transporter involved in bile acid uptake. The company is advancing NTCP programs for cholestatic liver diseases, initially focusing on pediatric biliary atresia.

Company

About ProQR Therapeutics NV.

ProQR Therapeutics N.V. Ordinary Shares represent ownership in ProQR Therapeutics N.V., a clinical-stage biotechnology company focused on RNA-based medicines. ProQR develops therapies built on its Axiomer RNA editing platform, which is designed to address genetic disorders with unmet medical needs. Its current work centers on discovering and developing novel therapeutic candidates for severe rare diseases, with particular attention to inherited conditions and other genetic targets. The company operates in the biotechnology and healthcare sectors, where RNA medicine is an important area of research because it aims to modify disease-related genetic messages rather than conventional protein targets. ProQR Therapeutics N.V. serves as a specialized participant in the broader life sciences market, supporting research, clinical development, and potential commercialization pathways for next-generation genetic therapies. Headquartered in Leiden, the Netherlands, the company also maintains a presence in Cambridge, Massachusetts.

CEO Mr. Daniel Anton de Boer · 186 employees · Netherlands · https://www.proqr.com